How reference pricing for pharmaceuticals can increase generic share of market: The Slovenian experience

Journal of Public Policy and Marketing

Volumn 26, Issue 1, 2007, Pages 89-101

  Podnar, Klement ^a   Molj, Bojan ^a   Golob, Urša ^b  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

^b Hofer Doo ^*  (Slovenia)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 34250902958     PISSN: 07439156     EISSN: 15477207     Source Type: Journal    
DOI: 10.1509/jppm.26.1.89     Document Type: Review

References (35)

1. Albreht, Tit, Marjan Cesen, Don Hindle, Elke Jakubowski, Boris Kramberger, Vesna Kerstin Petric, Marjan Premik, and Martin Toth (2002), Health Care Systems in Transition: Slovenia. Copenhagen: European Observatory on Health Care Systems.
2. Aronsson, Thomas, Mats A. Bergman, and Niklas Rudholm (2001), "The Impact of Generic Drug Competition on Brand Name Market Shares: Evidence from Micro Data," Review of Industrial Organization, 19 (4), 425-35.
3. Brekke, Kurt R., Astrid L. Grasdal, and Tor Helge Holmas (2006), "Regulation and Pricing of Pharmaceuticals: Reference Pricing or Price Cap Regulation?" working paper, Department of Economics, Health Economics Bergen, University of Bergen, (accessed November 28, 2006), [available at http://www.nhh.no/sam/res-publ/2006/30.pdf].
4. Danzon, Patricia (2001), "Reference Pricing: Theory and Evidence," working paper, The Wharton School, University of Pennsylvania.
5. _ and Michael F. Furukawa (2003), "Prices and Availability of Pharmaceuticals: Evidence from Nine Countries," Health Affairs, (October 29), (accessed August 18, 2006), [available at http://content. healthaffairs.org/cgi/content/full/hlthaff.w3.521vl/DC1].
6. _ and Jonathan D. Ketcham (2003), "Reference Pricing of Pharmaceuticals for Medicare: Evidence from Germany, the Netherlands and New Zealand," National Bureau of Economic Research Working Paper No. 10007.
7. Dickson, Michael and Heinz Redwood (1998), "Pharmaceutical Reference Prices: How Do They Work in Practice?" Pharmaeconomics, 14 (5), 471-79.
8. Ess, M. Silvia, Sebastian Schneeweiss, and Thomas D. Szucs (2003), "European Healthcare Policies for Controlling Drug Expenditure," Pharmaeconomics, 21 (2), 90-103.
9. The European Federation of Pharmaceutical Industries and Associations (2005), The Pharmaceutical Industry in Figures 2005, (accessed August 18, 2006), [available at http://www.efpia.org/6_publ/default.htm].
10. Festić, Mejra (2004), "Cost Containment for Public Pharmaceutical Expenditures in the European Union," Naše Gospodarstvo [Our Economy], 50 (1-2), 84-92.
11. Frank, Richard G. and David S. Salkever (1997), "Generic Entry and the Pricing of Pharmaceuticals," Journal of Economics and Management Strategy, 6 (1), 75-90.
12. Fürst, Jurij (2001), "Predpisovanje zdravil v letu 2000" ["Prescribing of Drugs in 2000"], Zdravnški Vestnlk [Slovene Medical Journal], 70 (10), 525-30.
13. _ (2003), "Predpisovanje zdravil v letu 2002" ["Prescribing of Drugs in 2002"], Zdravnški Vestnik [Slovene Medical Journal], 72 (3), 117-25.
14. _ (2004a), "Predpisovanje zdravil v letu 2003" ["Prescribing of Drugs in 2003"], Zdravnški Vestnik [Slovene Medical Journal], 73 (6), 477-85.
15. _ (2004b), Slovenia, Pricing and Reimbursement of Pharmaceuticals. Ljubljana: HIIS Internet Resources, (accessed November 30, 2004), [available from http://www.zzzs.si].
16. _ (2005), "Predpisovanje zdravil v letu 2004" ["Prescribing of Drugs in 2004"], Zdravnški Vestnik [Slovene Medical Journal], 74 (6), 345-50.
17. _ and Vita Samaluk (2006), "Predpisovanje zdravil v letu 2005" ["Prescribing of Drugs in 2005"], Zdravnški Vestnik {Slovene Medical Journal], 75 (6), 253-57.
18. Giuliani, Giovanni, Gisbert Selke, and Livio Garattini (1998), "The German Experience in Reference Pricing," Health Policy, 44 (1), 73-85.
19. HIIS (2003), Uvedba sistema medsebojno zamenljivih zdravil z najvišjo priznano vrednostjo [The Implementation of the Interchangeable Drugs System with the Maximum Reimbursed Price]. Ljubljana: HIIS Internet Resources, (accessed August 18, 2006), [available at http://www.zzzs.si].
20. Huttin, Christine (1999), "Drug Price Divergence in Europe: Regulatory Aspects," Health Affairs, 18 (May-June), 245-49.
21. _ (2002), "Experiences with Reference Pricing," International Journal of Risk & Safety in Medicine, 15 (1-2), 85-91.
22. Ioannides-Demos, Lisa L., Jospeh E. Ibrahim, and John J. McNeil (2002), "Reference-Based Pricing Schemes, Effect on Pharmaceutical Expenditure, Resource Utilisation and Health Outcomes," Pharmacoeconomics, 20 (9), 577-91.
23. Kalyanaram, Gurumurthy and Russell S. Winer (1995), "Empirical Generalizations from Reference Price Research," Marketing Science, 14 (3), 161-69.
24. Kanavos, Panos and Uwe Reinhardt (2003), "Reference Pricing for Drugs: Is It Compatible with U.S. Health Care?" Health Affairs, 22 (3), 16-30.
25. King, Derek R. and Panos Kanavos (2002), "Encouraging the Use of Generic Medicines: Implications for Transition Economies," Croatian Medical Journal, 43 (3), 462-69.
26. Kogovšek Vidmar, Tatjana (2005), "Evropski sistemi zdravstvenega varstva in zavarovanja, trg zdravil v Sloveniji in financiranje stroškov za zdravila, predpisana na Rp, lekarniška mreza ter položaj izvajalcev zdravstvenih storitev" ["European Systems of Health Insurance, Pharmaceutical Market in Slovenia and Financing of Prescription Medicines: Pharmaceutical Network and the Position of Slovenian Public Health Care Institutions"], working paper, Faculty of Pharmacy, University of Ljubljana.
27. Lopez-Casasnovas, Guilliem and Jaume Puig-Junoy (2000), "Review of Literature on Reference Pricing," Health Policy, 54 (2), 87-123.
28. Maio, Vittorio and Lamberto Manzoli (2002), "The Italian Health Care System: W.H.O. Ranking Versus Public Perception," P&T, 27 (6), 301-308.
29. Official Gazette of the Republic of Slovenia (2003), "Decree Adopting Criteria for Classification of Drugs," 13 (78), 11, 47-48.
30. Paraponaris, Alain, Pierre Verger, and B. Desquins (2004), "Delivering Generics Without Regulatory Incentives? Empirical Evi ence from French General Practitioners About Willingness to Prescribe International Non-Propriety Names," Health Policy, 70 (1), 23-32.
31. Primožič, Stanislav (2004), Generična in originalna zdravila v luč i regulatomih vprašanj in farmakoekonomike [Generic and Original Drugs in Light of Regulation and Pharmacoeconomics], (accessed November 30, 2005), [available from http://www2.gov.si/mz/mz-splet.nsf].
32. _ (2006), Cene zdravil v Sloveniji so v sorazmerju z evropskimi [Drug Prices in Slovenia Are in Proportion to EU Prices], Ljubljana: Ministry of Health Internet Resources, (accessed August 18, 2006), [available at http://www.mz.gov.si].
33. Thomas, Mary C., Jim Mann, and Sheila Williams (1998), "The Impact of Reference Pricing on Clinical Liped Control," New Zealand Journal of Medicine, 14 (August), 292-94.
34. U.S. Department of Commerce, International Trade Administration (2004), Pharmaceutical Price Controls in OECD Countries: Implications for U.S. Consumers, Pricing, Research and Development, and Innovation, (accessed October 14, 2006), [available at http://www.ita.doc.gov/td/chemicals/ drugpricingstudy.pdf].
35. World Health Organization (2006), About the ATC/DDD System, (accessed August 18, 2006), [available at http://www.whocc.no/atcddd/].